Despite scientific advances, many solid cancers, such as pancreatic adenocarcinoma (PAC) or recurrent high grade serous ovarian cancer (HGSOC), have remained practically incurable. We will identify each tumor's vulnerabilities separately for distinct subpopulations in order to combine the most potent drugs for maximal efficacy. This enables the design of new rational combinations to target multiple pre-existing and adaptive drug resistance mechanisms. By developing PAC and HGSOC organoid models, we aim to show the feasibility of these systems medicine methods to understand drug resistance for individual patients, that will ultimately inform an evidence-based treatment decision, or to provide insights into the development of new combinatorial therapies.

2022

2026